Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion

Acta Ophthalmologica

Volumn 87, Issue 1, 2009, Pages 77-81

  Rensch, Florian ^a   Jonas, Jost B ^a,b   Spandau, Ulrich H M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intravitreal Avastin ; Intravitreal bevacizumab; Macular oedema; Non ischaemic central retinal vein occlusion

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INTRAOCULAR PRESSURE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 58949085662     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01313.x     Document Type: Article

References (24)

1. Bakri PM, Snyder MR, Reid JM, Pulido JS Singh RJ (2007 Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 : 855 859.
2. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR Khan S (2006 Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26 : 871 876.
3. Central Retinal Vein Study Group (1997 Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115 : 486 491.
4. Costa RA, Jorge R, Calucci D, Melo LA Jr., Cardillo JA Scott IU (2007 Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27 : 141 149.
5. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Kelin BE, Wong TY Mitchell P (2007 Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 114 : 520 524.
6. Deutsche Retinologische Gesellschaft (2007 Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. [German Retina Society (2007): Recommendation for the implementation of intravitreal injections - statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)]. Klein Monatsbl Augenheilkd 224 : 559 566.
7. Ferrara DC, Koizumi H Spaide RF (2007 Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144 : 864 871.
8. Gelston CD, Olson JL Mandava N (2006 Macular oedema in central retinal vein occlusion treated with intravitreal triamcinolone. Acta Ophthalmol 84 : 314 318.
9. Hayreh SS (2005 Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24 : 493 519.
10. Heiduschka P, Fietz H, Hofmeister S et al. (2007 Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48 : 2814 2823.
11. Hoh AE, Schaal KB Dithmar S (2007 Retinale Zentralvenen- und Venenastverschlüsse. Aktueller Therapiestand in Deutschland, Österreich und der Schweiz. [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland]. Ophthalmologe 104 : 290 294.
12. Iturralde D, Spaide RF, Meyerle CB et al. (2006 Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 : 279 284.
13. Jaissle GB, Ziemssen F, Petermeier K et al. (2006 Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefäßverschlüssen. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe 103 : 471 475.
14. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G Spandau UH (2007 Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol 85 : 563 565.
15. La Cour M (2007 Intravitreal VEGF-inhibitors: is avastin a generic substitute for lucentis? Acta Ophthalmol Scand 85 : 2 4.
16. Matsumoto Y, Freund KB, Peiretti E, Cooney M, Ferrara DC Yannuzzi LA (2007 Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27 : 426 431.
17. Mohamed Q, Mcintosh RL, Saw SM Wong TY (2007 Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114 : 507 519.
18. Noma H, Funatsu H, Yamasaki M et al. (2005 Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140 : 256 261.
19. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P Enger C (1990 The natural course of central retinal vein occlusion. Am J Ophthalmol 110 : 118 123.
20. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA Avery RL (2007 Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27 : 419 425.
21. Rosenfeld PJ, Fung AE Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 : 336 339.
22. Schaal KB, Hoh AE, Scheuerle A, Schutt F Dithmar S (2007 Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäßverschlüsse. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe 104 : 285 289.
23. Spandau UH, Ihloff AK Jonas JB (2006 Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol 84 : 555 556.
24. Stahl A, Agostini H, Hansen LL Feltgen N (2007 Bevacizumab in retinal vein occlusion - results of a pro case series. Graefes Arch Clin Exp Ophthalmol 245 : 1429 1436.